<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antithrombin, concentrate from human plasma and recombinant human: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antithrombin, concentrate from human plasma and recombinant human: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Antithrombin, concentrate from human plasma and recombinant human: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8849" href="/d/html/8849.html" rel="external">see "Antithrombin, concentrate from human plasma and recombinant human: Drug information"</a> and <a class="drug drug_patient" data-topicid="11742" href="/d/html/11742.html" rel="external">see "Antithrombin, concentrate from human plasma and recombinant human: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135930"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Thrombate III</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F998669"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anticoagulant</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F55150180"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1867e778-589d-40c8-aa71-ee65a87e9d1e">Acquired antithrombin III deficiency, replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acquired antithrombin III deficiency, replacement</b>
<b> (in combination with standard anticoagulation [Heparin])</b>
<b>:</b> Very limited data available: Ideal dose-response not established:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Experts suggest using in combination with standard anticoagulation in patients with deep vein thrombosis, cerebral sinovenous thrombosis (CSVT), or pulmonary embolism who fail to respond clinically to standard anticoagulation treatment and who have low antithrombin (AT) levels based on age-appropriate reference ranges; there is no evidence to suggest that AT replacement improves outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482766'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving extracorporeal membrane oxygenation (ECMO): </i>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Lab-directed dosing</span> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28301908','lexi-content-ref-33214783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28301908','lexi-content-ref-33214783'])">Ref</a></span>): <b>Note: </b>Individualize dosing; calculate dose using the following formula: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Antithrombin dose required (units) = [(desired AT level % − baseline AT level %) x body weight (kg)] <b>divided</b> by 1.4</p>
<p style="text-indent:-2em;margin-left:10em;">Desired AT level % is 120% <b>or </b>an appropriate level for age and/or clinical indication (refer to institutional policy).</p>
<p style="text-indent:-2em;margin-left:10em;">Baseline AT level % is based on pretherapy AT levels (refer to institutional policy).</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Weight-directed dosing</span>: IV: 50 units/kg/dose as a single dose, may repeat to achieve therapeutic anticoagulation and/or appropriate serum antithrombin III level; dosing based on 2 retrospective studies. One retrospective, observational study evaluated pediatric patients on ECMO (n=35, median age: 6 months [range: 0.33 to 144 months]) who failed to achieve adequate anticoagulation despite increasing heparin doses and subsequently received AT supplementation (median dose: 50 units/kg [range: 20 to 92.6 units/kg]). AT supplementation increased AT levels and heparin anti-Xa levels; a single dose of AT was associated with a therapeutic heparin anti-Xa level for at least 48 hours. Only 10 patients required an additional dose due to falling heparin anti-Xa levels and AT levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31634932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31634932'])">Ref</a></span>). In another retrospective review of 77 patients on ECMO (n=36, mean age: 1.7 years ± 9.8 years), 50 units/kg as a single dose was administered to patients receiving heparin when AT level was &lt;80% as part of the anticoagulation protocol. No association was shown between AT level and bleeding, thrombosis, or heparin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27861430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27861430'])">Ref</a></span>). <b>Note:</b> High doses of AT (mean dose: 241 units/kg [range: 199 to 283 units/kg]) in infants have been reported with favorable outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24814836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24814836'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients NOT receiving ECMO</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28301908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28301908'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Lab-directed dosing</span>: <b>Note: </b>Individualize dosing; calculate dose using the following formula: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Antithrombin dose required (units) = [(desired AT level % − baseline AT level %) x body weight (kg)] <b>divided</b> by 1.4</p>
<p style="text-indent:-2em;margin-left:10em;">Desired AT level % is 120% <b>or </b>an appropriate level for age and/or clinical indication (refer to institutional policy).</p>
<p style="text-indent:-2em;margin-left:10em;">Baseline AT level % is based on pretherapy AT levels (refer to institutional policy).</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Weight-directed dosing</span>: IV: 50 units/kg/dose, may repeat to maintain goal AT level; <b>Note:</b> Dosing reported anecdotally based on reports from various institutions.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55150233"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F55150234"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F135933"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8849" href="/d/html/8849.html" rel="external">see "Antithrombin, concentrate from human plasma and recombinant human: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="484e1f86-9969-4bfa-9399-7f90d34ca9c5">Hereditary antithrombin deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary antithrombin deficiency:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Thrombate III:</i></b> Prophylaxis of thrombosis during surgical or obstetrical procedures or treatment of thromboembolism:</p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial loading dose: Dosing is individualized based on pretherapy antithrombin (AT) levels. The initial dose should raise AT levels to 120% and may be calculated based on the following formula:</p>
<p style="text-indent:-2em;margin-left:10em;margin-top:2em;">[(desired AT level % - baseline AT level %) x body weight (kg)] <b>divided</b> by 1.4 = units of antithrombin required</p>
<p style="text-indent:-2em;margin-left:8em;margin-top:2em;">For example, if a 70 kg adult patient had a baseline AT level of 57%, the initial dose would be:</p>
<p style="text-indent:-2em;margin-left:10em;margin-top:2em;">[(120% - 57%) x 70] divided by 1.4 = 3150 units</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: In general, subsequent dosing should be targeted to keep levels between 80% to 120%, which may be achieved by administering 60% of the initial loading dose every 24 hours. Adjustments may be made by adjusting dose or interval. Maintain level within normal range for 2 to 8 days depending on type of procedure/situation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a808e335-4215-44cc-96ab-a9bceeb02474">Intraoperative heparin resistance during cardiopulmonary bypass</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraoperative heparin resistance during cardiopulmonary bypass (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Thrombate III: </i></b>IV: Initial: 500 units once (dose can be rounded to the nearest vial size); a repeat dose of 500 units may be considered if activated clotting time remains subtherapeutic after the initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11828278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11828278'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990326"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987668"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F135907"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Chest pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Dizziness (2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Liver enzyme abnormalities (≤2%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Hematuria (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic &amp; oncologic: Hemorrhage (≥5%), hematoma (≤2%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Local: Infusion site reaction (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Hemarthrosis (≤2%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Blurred vision, chest tightness, chills, dizziness, dyspnea, fever, gastrointestinal fullness, muscle cramps, nausea, unpleasant taste, urticaria </p></div>
<div class="block coi drugH1Div" id="F135920"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Thrombate III: There are no contraindications listed in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to antithrombin, other anticoagulants, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F135904"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including severe hypersensitivity reactions (eg, anaphylaxis), may occur; monitor closely during infusions. If hypersensitivity symptoms occur, discontinue immediately and institute supportive emergency care.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Thrombate III: Thrombate III is AT collected from pooled human plasma (hpAT). A product of human plasma, it may potentially contain infectious agents which could transmit disease, including the Creutzfeldt-Jakob Disease (CJD) agent; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Infections suspected to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pharmacokinetic differences: Half-life and clearance differ significantly (~7 to 9 times) between the plasma-derived and the recombinant-derived product.</p></div>
<div class="block dosfc drugH1Div" id="F56328561"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Vial potency may vary; exact potency is labeled on each vial.</p></div>
<div class="block foc drugH1Div" id="F135914"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thrombate III: 500 units (1 ea); 1000 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F135900"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322994"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Thrombate III Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $5.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $4.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56328000"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 550 units (1 ea); 1100 units (1 ea)</p></div>
<div class="block admp drugH1Div" id="F55150236"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Thrombate III: Infuse over 10 to 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33214783','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33214783','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F135917"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Thrombate III: Infuse over 10 to 20 minutes.</p></div>
<div class="block sts drugH1Div" id="F135927"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Thrombate III: Store intact vials at temperatures not exceeding 25°C (77°F); avoid freezing. Administer within 3 hours after reconstitution. Do not refrigerate reconstituted product.</p></div>
<div class="block usep drugH1Div" id="F53565474"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of thromboembolism in patients with hereditary antithrombin deficiency undergoing surgical or obstetrical procedures; treatment and prevention of thromboembolism in patients with hereditary antithrombin deficiency (All indications: Thrombate III: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F52614843"><span class="drugH1">Medication Safety Issues</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sound-alike/look-alike issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Antithrombin may be confused with thrombin (topical)</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombate III may be confused with thrombin (topical)</p>
<p style="text-indent:-2em;margin-left:4em;">ATIII (abbreviation for Antithrombin) may be confused with ATII (abbreviation for Angiotensin II)</p></div>
<div class="block cyt drugH1Div" id="F13298762"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F135908"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Antithrombin may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): Antithrombin may enhance the anticoagulant effect of Heparins (Low Molecular Weight). <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F135923"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F135922"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The risk of thromboembolic events such as venous thromboembolism (VTE) is increased in patients with hereditary antithrombin (AT) deficiency. Pregnancy-induced physiologic changes also increase this risk; risk is dependent upon maternal antithrombin levels and personal or family history of thromboembolism (ACOG 197 2018). Thrombate III is approved for use in pregnant women with hereditary AT deficiency to replace endogenous antithrombin and reduce the risk of peripartum thromboembolism. Antithrombin replacement can be used in pregnant patients with hereditary AT deficiency in high-risk settings (eg, childbirth, miscarriage, surgery) when other anticoagulant therapy (eg, low molecular weight heparin [LMWH]) is withheld or as adjunctive therapy to LMWH in pregnant women at high risk for VTE (Bauer 2016; Ilonczai 2015; James 2017; Rogenhofer 2014).</p></div>
<div class="block mopp drugH1Div" id="F53565449"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Thrombate III: Antithrombin levels at baseline and post infusion as clinically indicated; signs and symptoms of bleeding; signs and symptoms of thrombosis; anticoagulation levels at baseline, post infusion, and as clinically indicated (eg, anti-Xa level for heparin).</p></div>
<div class="block rerp drugH1Div" id="F53565358"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Maintain antithrombin level in plasma &gt;80%; plasma AT levels are ~60% lower near term infants than levels observed in adults; premature infants may have levels lower than other neonates.</p></div>
<div class="block pha drugH1Div" id="F135903"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antithrombin is the primary physiologic inhibitor of <i>in vivo</i> coagulation. It is an alpha<sub>2</sub>-globulin. Its principal actions are the inactivation of thrombin, plasmin, and other active serine proteases of coagulation, including factors IXa, Xa, XIa, and XIIa. The inactivation of proteases is a major step in the normal clotting process. The strong activation of clotting enzymes at the site of every bleeding injury facilitates fibrin formation and maintains normal hemostasis. Thrombosis in the circulation would be caused by active serine proteases if they were not inhibited by antithrombin after the localized clotting process (Schwartz, 1989).</p>
<p style="text-indent:0em;margin-top:2em;">In patients with hereditary antithrombin (AT) deficiency, spontaneous thrombosis may occur due to decreased AT concentrations; therapy with human or recombinant AT restores functional AT activity. </p></div>
<div class="block phk drugH1Div" id="F135919"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma derived (Thrombate III):</p>
<p style="text-indent:-2em;margin-left:4em;">Half-life elimination: Biologic: 2.5 days (immunologic assay); 3.8 days (functional AT assay). Half-life may be decreased following surgery, with hemorrhage, acute thrombosis, and/or during heparin administration.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F135924"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anbinex | Antitrombina III UNC | At iii kedrion</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atenativ | Kybernin p | Thrombhibin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Thrombotrol vf</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Concentre d'antithrombine</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anbinex | Atenativ | Kybernin p</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anbinex | Antithrombin iii human | At iii nf | AT III thermoinaktiviert Immuno | Atenativ | Kybernin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Antithrombin iii baxter | At iii nf | At iii thermoinakt | Atenativ</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anbin | Atenativ | Kybernin p</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atenativ</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aclotine | Atenativ</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kybernin p</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kybernin p</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atenativ</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Kybernin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anbin | Antitrombina III | At iii kedrion | Atenativ | Atked | Kybernin p</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anthrobin | Neuart | Nonthron</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anti thrombin iii | Sk anti thrombin iii</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atenativ | Kybernin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Atend | Octati</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atenativ</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atenativ</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anti thrombin iii | Antithrombin iii g | Atenativ | Kybernin p</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Thrombate III</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Anbinex | Atenativ | Kybernin p</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Antithrombin iii immuno | Atenativ</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Antithrombin iii human</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Antithrombin iii baxter | Atenativ</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kybernin p</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Anbinex | Atenativ | Kybernin p</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atenativ | Kybernin p</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atenativ</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29939939">
<a name="29939939"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. [published correction appears in <i>Obstet Gynecol</i>. 2018;132(4):1069.] <i>Obstet Gynecol</i>. 2018;132(1):e18-e34. doi: 10.1097/AOG.0000000000002703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/29939939/pubmed" id="29939939" target="_blank">29939939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Antithrombin.1">
<a name="Antithrombin.1"></a>Antithrombin III (Human) [product monograph]. Mississauga, Ontario, Canada: Grifols Canada Ltd; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31634932">
<a name="31634932"></a>Jayakody Arachchillage DR, Gaspar M, Makhecha S, Laffan M. Use of antithrombin concentrate for acquired antithrombin deficiency in acutely unwell children receiving unfractionated heparin. <i>Semin Thromb Hemost</i>. 2019;45(8):859-864.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/31634932/pubmed" id="31634932" target="_blank">31634932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27281301">
<a name="27281301"></a>Bauer KA, Nguyen-Cao TM, Spears JB. Issues in the diagnosis and management of hereditary antithrombin deficiency. <i>Ann Pharmacother</i>. 2016;50(9):758-767. doi: 10.1177/1060028016651276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/27281301/pubmed" id="27281301" target="_blank">27281301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28301908">
<a name="28301908"></a>Ciolek A, Lindsley J, Crow J, Nelson-McMillan K, Procaccini D. Identification of cost-saving opportunities for the use of antithrombin III in adult and pediatric patients. <i>Clin Appl Thromb Hemost</i>. 2018;24(1):186-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/28301908/pubmed" id="28301908" target="_blank">28301908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33214783">
<a name="33214783"></a>Gordon SE, Heath TS, McMichael ABV, Hornik CP, Ozment CP. Evaluation of heparin anti-factor Xa levels following antithrombin supplementation in pediatric patients supported with extracorporeal membrane oxygenation. <i>J Pediatr Pharmacol Ther</i>. 2020;25(8):717-722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/33214783/pubmed" id="33214783" target="_blank">33214783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26226254">
<a name="26226254"></a>Ilonczai P, Oláh Z, Selmeczi A, et al. Management and outcome of pregnancies in women with antithrombin deficiency: a single-center experience and review of literature.<i> Blood Coagul Fibrinolysis</i>. 2015;26(7):798-804. doi: 10.1097/MBC.0000000000000348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/26226254/pubmed" id="26226254" target="_blank">26226254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28689083">
<a name="28689083"></a>James AH, Bates SM, Bauer KA, et al. Management of hereditary antithrombin deficiency in pregnancy. <i>Thromb Res</i>. 2017;157:41-45. doi: 10.1016/j.thromres.2017.05.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/28689083/pubmed" id="28689083" target="_blank">28689083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12675726">
<a name="12675726"></a>Konkle BA, Bauer KA, Weinstein R, et al, “Use of Recombinant Human Antithrombin in Patients With Congenital Antithrombin Deficiency Undergoing Surgical Procedures,” <i>Transfusion</i>, 2003, 43(3):390-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/12675726/pubmed" id="12675726" target="_blank">12675726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11828278">
<a name="11828278"></a>Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. <i>J Thorac Cardiovasc Surg</i>. 2002;123(2):213-217. doi: 10.1067/mtc.2002.119060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/11828278/pubmed" id="11828278" target="_blank">11828278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482766">
<a name="30482766"></a>Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. <i>Blood Adv</i>. 2018;2(22):3292-3316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/30482766/pubmed" id="30482766" target="_blank">30482766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19141163">
<a name="19141163"></a>Patnaik MM and Moll S, “Inherited Antithrombin Deficiency: A Review,” <i>Haemophilia</i>, 2008, 14(6):1229-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/19141163/pubmed" id="19141163" target="_blank">19141163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19404531">
<a name="19404531"></a>Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. <i>Thromb Haemost</i>. 2009 May;101(5):806-812. Review.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/19404531/pubmed" id="19404531" target="_blank">19404531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23999648">
<a name="23999648"></a>Rogenhofer N, Bohlmann MK, Beuter-Winkler P, et al. Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. <i>Ann Hematol</i>. 2014;93(3):385-392. doi: 10.1007/s00277-013-1892-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/23999648/pubmed" id="23999648" target="_blank">23999648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24814836">
<a name="24814836"></a>Ryerson LM, Bruce AK, Lequier L, Kuhle S, Massicotte MP, Bauman ME. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. <i>ASAIO J</i>. 2014;60(5):559-563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/24814836/pubmed" id="24814836" target="_blank">24814836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2679072">
<a name="2679072"></a>Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. <i>Am J Med</i>. 1989, 87(3B):53S-60S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/2679072/pubmed" id="2679072" target="_blank">2679072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thrombate.1">
<a name="Thrombate.1"></a>Thrombate III (antithrombin III) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18327412">
<a name="18327412"></a>Tiede A, Tait RC, Shaffer DW, et al. Antithrombin Alfa in Hereditary Antithrombin Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations. <i>Thromb Haemost</i>. 2008, 99(3):616-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/18327412/pubmed" id="18327412" target="_blank">18327412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27861430">
<a name="27861430"></a>Todd Tzanetos DR, Myers J, Wells T, Stewart D, Fanning JJ, Sullivan JE. The use of recombinant antithrombin III in pediatric and neonatal ECMO patients. <i>ASAIO J</i>. 2017;63(1):93-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-pediatric-drug-information/abstract-text/27861430/pubmed" id="27861430" target="_blank">27861430</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 130359 Version 34.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
